Table 1.

Comparisons of clinical characteristics

	1985–2006	2007–2014	P value
	N = 123	N = 149
Mean age	30(22–57)	31(21–54)	0.25
Median gravidity	2(1–10)	2(1–8)	0.17
Median parity	1(1–9)	1(1–4)	0.56
Previous hydatidiform mole or invasive mole	21(17 %)	27(18 %)	0.82
Median interval from index pregnancy, months	7(0–216)	13(0–348)	0.002
Interval from index pregnancy <4 mo	47(38 %)	31(21 %)	0.002
Interval from index pregnancy >12 mo	36(29 %)	75(50 %)	0.000
Mean pretreatment β-hCG mIU/ml	119692 (6.5-3120000)	103554 (negative-2876010)	0.67
Pretreatment >400,000 β-hCG mIU/ml	5(4 %)	10(7 %)	0.34
Metastatic disease	98(80 %)	128(86 %)	0.17
Metastatic sites ≥2	38(31 %)	39(26 %)	0.39
Symptoms
Abnormal uterine bleeding	91(74 %)	111(74 %)	0.92
Hemoptysis	14(11 %)	13(9 %)	0.47
Central neural system symptoms	12(10 %)	4(3 %)	0.17
Fetal death or stillbirth	3(2 %)	11(7 %)	0.07
Resistance to multiagent chemotherapy	49(40 %)	72(48 %)	0.16
Mean chemotherapy courses	8.5(1–27)	7.5(1–26)	0.44
Numbers of surgeries	75(61 %)	88(59 %)	0.75
Mean FIGO score	9.2(2–19)	9.4(2–22)	0.59
FIGO score >12	25(20 %)	31(21 %)	0.92
FIGO stage
I	24(20 %)	22(15 %)	0.30
II	9(7 %)	0(0 %)	n/aa
III	66(54 %)	95(64 %)	0.09
IV	24(19 %)	32(21 %)	0.69

^a chi-square test undefined